Procept BioRobotics initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of Procept BioRobotics (PRCT) with an Overweight rating and $105 price target Procept offers a clinically differentiated treatment for patients with enlarged prostates who often suffer from lower urinary tract symptoms and the firm’s work suggests plenty of penetration remaining for PRCT in prostates with only 8% penetration today, leaving “a long tail for growth,” the analyst tells investors.